Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.

A six-week double-blind placebo-controlled trial of fluvoxamine was undertaken in 46 patients suffering from panic disorder with or without agoraphobia diagnosed by DSM-III-R guidelines. Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day. Weekly evaluation included a diary in which the number, severity, and duration of full-blown and limited panic attacks and the duration and severity of anticipating fear, CAS, GAS, CGI, HAM-D, adverse effects and the number of capsules not taken were noted. Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was significantly more effective with regard to the diminution in the number of limited panic attacks and showed a tendency to significance in respect of GAS and CGI. Plasma levels of fluvoxamine were measured at the end of week one and at the end of the study. Most patients with complete remission at the end of the study were found in the verum group with plasma fluvoxamine levels ranging from 10 to 100ng/ml. It is suggested that therapeutic response might be maximized by monitoring fluvoxamine concentrations in blood.
AuthorsJ Sandmann, B Lörch, B Bandelow, S Härtter, P Winter, C Hiemke, O Benkert
JournalPharmacopsychiatry (Pharmacopsychiatry) Vol. 31 Issue 4 Pg. 117-21 (Jul 1998) ISSN: 0176-3679 [Print] GERMANY
PMID9754844 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Anxiety Agents
  • Serotonin Uptake Inhibitors
  • Fluvoxamine
  • Adolescent
  • Adult
  • Aged
  • Anti-Anxiety Agents (blood, therapeutic use)
  • Double-Blind Method
  • Drug Monitoring
  • Female
  • Fluvoxamine (blood, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Panic Disorder (blood, drug therapy)
  • Psychiatric Status Rating Scales
  • Serotonin Uptake Inhibitors (blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: